Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice

被引:693
作者
Huang, WT
Na, L
Fidel, PL
Schwarzenberger, P
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70122 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70122 USA
关键词
D O I
10.1086/422329
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cells are required for normal host defense against fungal infection, and individuals with T cell - deficiency syndromes are highly susceptible to fungal pathogens. Interleukin (IL)-17A is a proinflammatory cytokine that interconnects myeloid and lymphoid host defense. The role of murine ( m) IL-17A/mIL-17A receptor ( R) interactions was evaluated in a murine model of systemic candidiasis. In response to systemic challenge with Candida albicans, expression of mIL-17A was induced, and IL-17AR knockout ( IL-17AR(-/-)) mice had dose-dependent, substantially reduced survival. Fungal burden in the kidneys of IL-17AR(-/-) mice was dramatically increased (25-fold at 96 h). In IL-17AR(-/-) mice, both mobilization of peripheral neutrophils and their influx to infected organs were significantly impaired and delayed. In vivo expression of mIL-17A protected normal mice from a lethal dose of C. albicans (100% at day 7 and 65% at day 42). The data suggest that the mIL-17A/mIL-17AR system is required for normal fungal host defense in vivo. IL-17A could have potential as a therapeutic cytokine for systemic C. albicans infections in immunocompromised patients with cancer or advanced acquired immunodeficiency syndrome.
引用
收藏
页码:624 / 631
页数:8
相关论文
共 30 条
[1]  
Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
[2]   Both CD4+ and CD8+ lymphocytes reduce the severity of tissue lesions in murine systemic candidiasis, and CD4+ cells also demonstrate strain-specific immunopathological effects [J].
Ashman, RB ;
Fulurija, A ;
Papadimitriou, JM .
MICROBIOLOGY-SGM, 1999, 145 :1631-1640
[3]  
Basu S, 2000, BLOOD, V95, P3725
[4]   The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer [J].
Bodey, GP ;
Mardani, M ;
Hanna, HA ;
Boktour, M ;
Abbas, J ;
Girgawy, E ;
Hachem, RY ;
Kontoyiannis, DP ;
Raad, II .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05) :380-385
[5]   ACQUIRED-IMMUNITY TO SYSTEMIC CANDIDIASIS IN IMMUNODEFICIENT MICE [J].
CANTORNA, MT ;
BALISH, E .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (05) :936-943
[6]   CAUSES OF DEATH IN ADULTS WITH ACUTE-LEUKEMIA [J].
CHANG, HY ;
RODRIGUEZ, V ;
NARBONI, G ;
BODEY, GP ;
LUNA, MA ;
FREIREICH, EJ .
MEDICINE, 1976, 55 (03) :259-268
[7]   DIFFERENTIAL-EFFECTS OF CD4+ AND CD8+ CELLS IN ACUTE, SYSTEMIC MURINE CANDIDOSIS [J].
COKER, LA ;
MERCADAL, CM ;
ROUSE, BT ;
MOORE, RN .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 51 (03) :305-306
[8]  
Fulurija A, 1997, J MED VET MYCOL, V35, P197
[9]   Fungemia in HIV-infected patients: A 12-year study in a tertiary care hospital [J].
Garbino, J ;
Kolarova, L ;
Lew, D ;
Hirschel, B ;
Rohner, P .
AIDS PATIENT CARE AND STDS, 2001, 15 (08) :407-410
[10]  
HAMOOD M, 1994, MYCOSES, V37, P93, DOI 10.1111/j.1439-0507.1994.tb00783.x